Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy

Technology appraisal guidance
Reference number: TA242
Published: 25 January 2012

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appendix A matrix of stakeholders

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appendix A matrix of stakeholders

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): appendix A matrix of stakeholders
09 February 2015
(101.49 Kb 29 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 06 February 2015